Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications

Cardiovasc Res. 2020 Jun 1;116(7):e87-e89. doi: 10.1093/cvr/cvaa096.

Authors

Eleanor Murray¹, Maciej Tomaszewski², Tomasz J Guzik¹

Affiliations

¹ Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, 126 University Place, University of Glasgow, Glasgow G12 8TA, UK.
² Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.

No abstract available

Keywords: ACE inhibitor; COVID-19; Hypertension; SARS-CoV-2.

Publication types

Review

MeSH terms

Angiotensin-Converting Enzyme 2
Animals
Betacoronavirus*
COVID-19
Clinical Trials as Topic*
Coronavirus Infections / virology*
Humans
Pandemics
Peptidyl-Dipeptidase A / immunology*
Pneumonia, Viral / virology*
SARS-CoV-2

Substances

Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2